BRAF and neoplasm: Recent studies have begun to associate selected variant and fusions with BRAF V600E-like vs. RAS-like (or non-BRAF-non-RAS) pathway signaling, iodine metabolism, neoplasm histology, risk of lymph node metastasis, risk of recurrence, and risk of mortality (3, 9).